GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and ...

GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 women across England ...

Cadonilimab plus lenvatinib showed promising antitumor activity in patients with advanced endometrial cancer who have experienced disease progression after prior platinum-based chemotherapy,” said ...

Endometrial cancer is one of the few cancers that doesn’t stay quiet. That’s why you should never brush off spotting between periods or any bleeding after menopause. When caught early, this ...

Endometrial cancer is a type of tumour that arises in the tissue lining the uterus. Most endometrial cancers are adenocarcinomas; that is, cancers formed from cells that make and release mucus and ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today ...

The combination of lenvatinib and pembrolizumab showed promising results in treating recurrent endometrial carcinoma, demonstrating significant antitumor activity and improved survival rates compared ...

Jemperli was approved for similar expanded use in endometrial cancer in the United States in August 2024. The drug is also approved for second-line endometrial cancer and dMMR recurrent or ...